中国免疫学杂志
中國免疫學雜誌
중국면역학잡지
CHINESE JOURNAL OF IMMUNOLOGY
2015年
6期
758-760,763
,共4页
杨大刚%王众%王惠群%孙诚谊
楊大剛%王衆%王惠群%孫誠誼
양대강%왕음%왕혜군%손성의
Plk1%Chk1/2%HepG2%原发性肝癌
Plk1%Chk1/2%HepG2%原髮性肝癌
Plk1%Chk1/2%HepG2%원발성간암
Plk1%Chk1/2%HepG2 cell%Primary hepatic carcinoma
目的::研究保罗样激酶1(Polo-like kinase1,Plk1)、细胞周期检测点激酶1、2(Checkpoint kinase 1/2,Chk1/2)在原发性肝癌组织与人肝癌细胞HepG2中的表达情况。方法:使用免疫组织化学Envision法检测40例原发性肝癌组织及16例肝非肿瘤组织中Plk1、Chk1/2蛋白的表达。提取培养后的HepG2细胞蛋白。利用蛋白免疫印记( Western blot)技术定性分析Plk1、Chk1/2蛋白在HepG2细胞中的表达情况,并测定灰度值进行定量分析。结果:原发性肝癌组织中Plk1、Chk1蛋白的阳性表达率分别是57.5%、75%,高于它们在肝非瘤组织中的表达率0%、25.0%(P<0.05)。 Chk2在原发性肝癌组织中的表达阳性率22.5%,低于肝非肿瘤组织中的表达率56.3%(P<0.05)。 Plk1、Chk1/2蛋白在HepG2细胞中均有表达。其相对表达量分别是:0.39±0.0226、0.08±0.0249、0.01±0.0066,三者之间的差异均有统计学意义,其表达的顺序依次为Plk1>Chk1>Chk2。结论:Plk1、Chk1蛋白在原发性肝癌组织中表达上调,而Chk2蛋白在原发性肝癌组织中表达下调。 Plk1、Chk1/2基因作为细胞周期调控中的重要激酶在HepG2细胞中均有表达,其表达顺序为Plk1>Chk1>Chk2。Plk1、Chk1具有相对意义的肿瘤选择性表达,可能成为肝癌生物治疗中新的治疗靶点。
目的::研究保囉樣激酶1(Polo-like kinase1,Plk1)、細胞週期檢測點激酶1、2(Checkpoint kinase 1/2,Chk1/2)在原髮性肝癌組織與人肝癌細胞HepG2中的錶達情況。方法:使用免疫組織化學Envision法檢測40例原髮性肝癌組織及16例肝非腫瘤組織中Plk1、Chk1/2蛋白的錶達。提取培養後的HepG2細胞蛋白。利用蛋白免疫印記( Western blot)技術定性分析Plk1、Chk1/2蛋白在HepG2細胞中的錶達情況,併測定灰度值進行定量分析。結果:原髮性肝癌組織中Plk1、Chk1蛋白的暘性錶達率分彆是57.5%、75%,高于它們在肝非瘤組織中的錶達率0%、25.0%(P<0.05)。 Chk2在原髮性肝癌組織中的錶達暘性率22.5%,低于肝非腫瘤組織中的錶達率56.3%(P<0.05)。 Plk1、Chk1/2蛋白在HepG2細胞中均有錶達。其相對錶達量分彆是:0.39±0.0226、0.08±0.0249、0.01±0.0066,三者之間的差異均有統計學意義,其錶達的順序依次為Plk1>Chk1>Chk2。結論:Plk1、Chk1蛋白在原髮性肝癌組織中錶達上調,而Chk2蛋白在原髮性肝癌組織中錶達下調。 Plk1、Chk1/2基因作為細胞週期調控中的重要激酶在HepG2細胞中均有錶達,其錶達順序為Plk1>Chk1>Chk2。Plk1、Chk1具有相對意義的腫瘤選擇性錶達,可能成為肝癌生物治療中新的治療靶點。
목적::연구보라양격매1(Polo-like kinase1,Plk1)、세포주기검측점격매1、2(Checkpoint kinase 1/2,Chk1/2)재원발성간암조직여인간암세포HepG2중적표체정황。방법:사용면역조직화학Envision법검측40례원발성간암조직급16례간비종류조직중Plk1、Chk1/2단백적표체。제취배양후적HepG2세포단백。이용단백면역인기( Western blot)기술정성분석Plk1、Chk1/2단백재HepG2세포중적표체정황,병측정회도치진행정량분석。결과:원발성간암조직중Plk1、Chk1단백적양성표체솔분별시57.5%、75%,고우타문재간비류조직중적표체솔0%、25.0%(P<0.05)。 Chk2재원발성간암조직중적표체양성솔22.5%,저우간비종류조직중적표체솔56.3%(P<0.05)。 Plk1、Chk1/2단백재HepG2세포중균유표체。기상대표체량분별시:0.39±0.0226、0.08±0.0249、0.01±0.0066,삼자지간적차이균유통계학의의,기표체적순서의차위Plk1>Chk1>Chk2。결론:Plk1、Chk1단백재원발성간암조직중표체상조,이Chk2단백재원발성간암조직중표체하조。 Plk1、Chk1/2기인작위세포주기조공중적중요격매재HepG2세포중균유표체,기표체순서위Plk1>Chk1>Chk2。Plk1、Chk1구유상대의의적종류선택성표체,가능성위간암생물치료중신적치료파점。
Objective:To investigate the expression of Plk1 ( Polo-like kinase 1 ) and Chk1/2 ( Checkpoint kinase 1/2 ) in primary hepatic carcinoma tissue and HepG2 cell. Methods: Using immunohistochemistry chemical method detected expression of Plk1,Chk1/2 protein in 40 cases of primary hepatic carcinoma tissue and 16 cases of non-tumor tissue of liver. Western blot was applied to detect the expression of Plk1 and Chk1/2 protein in HepG2 cells, and gray value was measured by using the quantitative analysis. Results:The positive rate of Plk1,Chk1/2 protein expression in primary hepatic carcinoma was 57. 5%,75. 0% and 22. 5%respectively,compared with positive rate in the liver of non-tumor tissue were 0%,25. 0% and 56. 3%. The expression of Plk1 and Chk1 protein in primary hepatic carcinoma tissue is higher than that in non-tumor tissue of liver,and the difference was statistically sig-nificant( P<0. 05 ) . The expression of Chk2 in primary hepatic carcinoma was lower than that in hepatic non-tumor tissue, and the difference was statistically significant(P<0. 05) too. The expression of Plk1,Chk1/2 protein were detected in HepG2 cells and the relative expression rate of Plk1,Chk1/2 protein were 0.39±0.0226,0.08±0.0249 and 0.01±0.0066 respectively,the difference between them was statistically significant. The expression degree was Plk1>Chk1>Chk2. Conclusion: Plk1,Chk1 protein in primary hepatic carcinoma was up-regulated,while Chk2 protein was down-regulated in these tissues. The expression degree was Plk1> Chk1>Chk2. There were relatively selective expression in primary hepatic carcinoma tissue of Plk1,Chk1 protein,then Plk1 and Chk1 might be ideal targets for therapy of primary hepatic carcinoma.